Regeneron Pharmaceuticals, Inc. — FY2015 Form 10-K Summary
Business context and reporting period
Regeneron is an integrated biopharmaceutical company engaged in drug discovery, development, manufacturing, and commercialization. This filing covers the fiscal year ended December 31, 2015, with quarterly information for the fourth quarter. The company operated as one business segment and marketed EYLEA, Praluent, and ARCALYST.
- EYLEA remained the principal commercial product, with U.S. and ex-U.S. commercialization conducted with Bayer HealthCare.
- Praluent was approved in the United States in July 2015 and in the European Union in September 2015, with Sanofi.
- The clinical pipeline included 13 candidates, including sarilumab, dupilumab, fasinumab, REGN2222, evinacumab, and REGN2810.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Total revenues | $4,103.7 million | $2,819.6 million | +45.5% |
| Net product sales | $2,689.5 million | $1,750.8 million | +53.6% |
| Collaboration revenue | $1,339.4 million | $1,036.9 million | +29.2% |
| Research and development expense | $1,620.6 million | $1,271.4 million | +27.5% |
| Selling, general and administrative expense | $838.5 million | $519.3 million | +61.5% |
| Income from operations | $1,251.9 million | $823.9 million | +52.0% |
| Net income | $636.1 million | $338.1 million | +88.1% |
| Diluted earnings per share | $5.52 | $2.98 | +85.2% |
| Operating margin | 30.5% | 29.2% | +1.3 points |
| Net margin | 15.5% | 12.0% | +3.5 points |
- U.S. EYLEA net product sales were $2,676.0 million, up from $1,736.4 million in 2014. ARCALYST sales were $13.5 million, versus $14.4 million.
- Praluent net product sales recorded by Sanofi were $10.5 million. Regeneron recorded its share of collaboration losses, including launch and commercialization costs, within Sanofi collaboration revenue.
- Sanofi collaboration revenue increased to $758.9 million from $541.3 million, while Bayer HealthCare collaboration revenue increased to $580.5 million from $495.6 million.
- Net cash provided by operating activities was $1,330.8 million, compared with $752.4 million in 2014.
- Capital expenditures were $677.9 million, compared with $333.0 million, reflecting major manufacturing and facility expansion.
- Cash and cash equivalents were $809.1 million and total cash, cash equivalents, and marketable securities were $1,677.4 million at year-end.
- The company had $750.0 million of available borrowing capacity under a new revolving credit facility and no borrowings outstanding under it.
- Convertible senior notes had a $10.8 million carrying value at year-end, with $11.2 million principal outstanding and maturity on October 1, 2016.
Material changes versus the prior comparable period
- Revenue growth was driven primarily by higher EYLEA volume and increased ex-U.S. EYLEA collaboration profits.
- R&D spending increased $349.2 million, led by expanded development and manufacturing activities for dupilumab, fasinumab, REGN2222, and other candidates.
- SG&A increased $319.3 million, principally due to higher headcount, stock-based compensation, and commercialization spending for EYLEA and Praluent.
- Non-cash compensation expense increased to $459.0 million from $321.8 million.
- The July 2015 Sanofi immuno-oncology collaboration produced $640.0 million of aggregate upfront payments, of which $600.0 million remained deferred at year-end.
- The company entered into a fasinumab collaboration with Mitsubishi Tanabe Pharma and received a $10.0 million upfront payment.
- The amended ZALTRAP agreement transferred worldwide development and commercialization responsibility to Sanofi and eliminated Regeneron's prior contingent obligation to reimburse approximately $461 million of development costs.
- Regeneron revised prior-period financial statements for certain stock-option accounting errors and other corrections. Management stated the errors were not material to previously issued financial statements.
- Fourth-quarter 2015 revenue was $1,098.1 million and net income was $155.0 million, compared with fourth-quarter 2014 revenue of $802.3 million and revised net income of $90.1 million.
Guidance, outlook, commentary, risks, and unusual items
- Management expected 2016 capital expenditures of approximately $580 million to $680 million, primarily for the Limerick, Ireland facility, Tarrytown improvements, and Rensselaer manufacturing expansion.
- Management stated that existing capital resources, operating cash flows, collaboration funding, and revolving-credit availability were expected to support operating needs for the foreseeable future, but no revenue or earnings guidance was provided.
- Management expected the effective tax rate to remain negatively affected in 2016 by the geographic mix of profits and losses. Cash tax payments were expected to be substantially higher than in 2015.
- Profitability and cash flow remained highly dependent on continued EYLEA commercialization. U.S. EYLEA represented 65% of total revenue in 2015.
- Customer concentration was significant: Besse Medical accounted for 67% of total gross product revenue, and one customer represented 68% of net trade receivables at year-end.
- Praluent faced reimbursement, pricing, competitive, safety, and post-approval risks. The ODYSSEY OUTCOMES cardiovascular-outcomes trial was expected to complete in 2017, and its results could affect the product’s commercial prospects.
- Amgen litigation over Praluent patents was scheduled for trial in March 2016, with a potential permanent-injunction hearing shortly thereafter. Regeneron could not estimate a loss range.
- Genentech and City of Hope asserted patent claims concerning recombinant antibody production; related district-court and USPTO proceedings remained unresolved.
- Patent litigation involving Regeneron’s antibody-discovery technology also remained unresolved. Subsequent to year-end, a U.K. court invalidated two asserted patents on insufficiency grounds, and Regeneron planned to appeal.
- Contingent reimbursement obligations were approximately $1.832 billion to Sanofi under the antibody collaboration and $258 million to Bayer HealthCare for EYLEA development costs.
- Manufacturing capacity, single-source suppliers, third-party fill/finish providers, regulatory compliance, product quality, and supply interruptions were identified as material risks.
- Regeneron recorded $20.2 million of expense for previously inventoried ZALTRAP commercial supplies following the amended agreement and paid $573.5 million during 2015 to reduce outstanding warrant obligations.
Most important facts for investors to verify
- Whether EYLEA growth, pricing, reimbursement, and market share remain sufficient to offset product concentration risk.
- Praluent prescription trends, formulary access, collaboration losses, competitive positioning versus Repatha, and results of the ODYSSEY OUTCOMES trial.
- Regulatory and clinical progress for sarilumab, dupilumab, fasinumab, REGN2222, REGN2810, and other pipeline programs.
- Outcomes and potential commercial impact of the Amgen, Genentech/City of Hope, and antibody-platform patent proceedings.
- Actual 2016 capital spending, manufacturing ramp-up at Limerick and Rensselaer, and the company’s ability to meet product demand.
- Future cash requirements, including the remaining convertible notes, lease obligations, collaboration reimbursements, purchase commitments, tax payments, and warrant-related payments.
- The timing and accounting impact of recognizing deferred Sanofi and other collaboration revenue.
- Effects of revised stock-option accounting, estimated rebates and chargebacks, inventory reserves, and the company’s high stock-based compensation expense.